Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
IDT Biologika announced the NIAID of the NIH has awarded the company a new Task Order within the 10-year contract to provide manufacturing of five E. coli Master Cell Banks.
read more
IDT Biologika and Exothera announced a collaboration to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s broad range ...
read more
A major manufacturer of human vaccines designed to address some of the world’s most dangerous infectious diseases, IDT Biologika today announced it has completed and certified the construction of a large-scale production facility dedicated to filling...
read more
Completing a major expansion of its biologics and vaccines production facility in Germany late last year, IDT Biologika established highly automated filling and freeze-drying operations, establishing the basis for large scale commercial manufacturing...
read more
IGI Laboratories, Inc., a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to six.
read more
Tuesday, November 06, 2012
IGI Laboratories, Inc., a New Jersey based topical generic pharmaceutical company, announced today that the Company will launch its first IGI labeled generic products later this year.
read more
Wednesday, December 19, 2012
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced that Dr. Kenneth Miller has been appointed Senior Vice President of R&D at IGI Laboratories, Inc. effective December 17, 2012.
read more
Thursday, December 27, 2012
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it closed a private placement on December 21, 2012 for a gross proceeds of $2.0 million. The Company issued 1,965,740 shares of the Company’s common ...
read more
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based pharmaceutical company, today announced that Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of IGI Laboratories, Inc. effective July 30, 2012.
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its second abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The ...
read more
Wednesday, November 06, 2013
Jason Grenfell-Gardner, President and CEO of the Company, commented, "This submission brings our total number of abbreviated new drug applications on file with the FDA to thirteen. We believe our current pipeline of submissions pending approval by ...
read more